Literature review of human papillomavirus vaccine acceptability among women over 26 years

Lora L. Black, Gregory D. Zimet, Mary B. Short, Lynne Sturm, Susan L. Rosenthal

Research output: Contribution to journalReview article

53 Scopus citations


Vaccines for the human papillomavirus (HPV) are currently licensed for females, ages 9 through 26 years old in the U.S., and for adult women up to 45 years in some countries such as Australia. As licensure for adult women, over 26 years, is sought in other countries, it will be important to determine the acceptability to them. We reviewed the available articles on adult opinions and acceptability of vaccinating women against HPV. Predictors of acceptability included barriers, knowledge, risk, age, and marital status. Overall, acceptability rates were high, if adequate information was given and the cost was affordable.

Original languageEnglish (US)
Pages (from-to)1668-1673
Number of pages6
Issue number11
StatePublished - Mar 10 2009



  • Acceptability
  • Adult women
  • Human papillomavirus vaccine
  • Sexually transmitted diseases

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this